Skip to main content
Clinical Journal of the American Society of Nephrology : CJASN logoLink to Clinical Journal of the American Society of Nephrology : CJASN
. 2020 Nov 9;15(12):1817. doi: 10.2215/CJN.16691020

Correction

PMCID: PMC7769035  PMID: 33168634

Fernando Caravaca-Fontán, Montserrat M. Díaz-Encarnación, Laura Lucientes, Teresa Cavero, Virginia Cabello, Gema Ariceta, Luis F. Quintana, Helena Marco, Xoana Barros, Natalia Ramos, Nuria Rodríguez-Mendiola, Sonia Cruz, Gema Fernández-Juárez, Adela Rodríguez, Ana Pérez de José, Cristina Rabasco, Raquel Rodado, Loreto Fernández, Vanessa Pérez Gómez, Ana I. Ávila, Luis Bravo, Javier Lumbreras, Natalia Allende, Maria Dolores Sanchez de la Nieta, Eva Rodríguez, Teresa Olea, Marta Melgosa, Ana Huerta, Rosa Miquel, Carmen Mon, Gloria Fraga, Alberto de Lorenzo, Juliana Draibe, Marta Cano-Megías, Fayna González, Amir Shabaka, Maria Esperanza López-Rubio, María Ángeles Fenollosa, Luis Martín-Penagos, Iara Da Silva, Juana Alonso Titos, Santiago Rodríguez de Córdoba, Elena Goicoechea de Jorge, Manuel Praga, and on behalf of the Spanish Group for the Study of Glomerular Diseases GLOSEN: Mycophenolate Mofetil in C3 Glomerulopathy and Pathogenic Drivers of the Disease. Clin J Am Soc Nephrol 15: 1287–1298, 2020; DOI: https://doi.org/10.2215/CJN.15241219.

Because of an author error, the reference groups were provided in error in Supplemental Tables 5, 7, 9, and 11. Additionally, the percentages of tubular atrophy/interstitial fibrosis in Supplemental Table 8 were incorrect. The Supplemental Material file has been corrected.

Footnotes

Published online ahead of print. Publication date available at www.cjasn.org.


Articles from Clinical Journal of the American Society of Nephrology : CJASN are provided here courtesy of American Society of Nephrology

RESOURCES